Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: Nov 14, 2024
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the third quarter ended September 30, 2024.
Read more at globenewswire.com
